Compare SMID & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SMID | IPHA |
|---|---|---|
| Founded | 1960 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 206.7M | 174.2M |
| IPO Year | 1995 | 2019 |
| Metric | SMID | IPHA |
|---|---|---|
| Price | $33.07 | $1.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 9.2K | ★ 564.9K |
| Earning Date | 11-13-2025 | 09-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 81.92 | N/A |
| EPS | ★ 2.22 | N/A |
| Revenue | ★ $88,866,000.00 | $14,839,695.00 |
| Revenue This Year | N/A | $22.29 |
| Revenue Next Year | N/A | $43.90 |
| P/E Ratio | $15.40 | ★ N/A |
| Revenue Growth | ★ 16.37 | N/A |
| 52 Week Low | $25.13 | $1.47 |
| 52 Week High | $50.75 | $3.51 |
| Indicator | SMID | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 38.28 | 48.99 |
| Support Level | $33.36 | $1.85 |
| Resistance Level | $36.50 | $1.96 |
| Average True Range (ATR) | 1.97 | 0.08 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 22.78 | 60.71 |
Smith-Midland Corp through its subsidiaries invents, develops, manufactures, markets, sells, and installs precast concrete products for primary use in the construction, highway, utilities, and farming industries. The firm's customers are general contractors and federal, state, and local transportation authorities. Its products include Slenderwall, JJhooks, Softsound, Sierra Wall and Easi set. A substantial portion of the company's business is derived from local, state, and federal building projects. The company generates revenues predominantly from the sale, leasing, licensing, shipping, and installation of precast concrete products for the construction, utility, and farming industries.
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.